Sales & Support: +44 (0)1223 316 855

Seracare reference materials: Seraseq

The Seraseq® NGS reference materials from SeraCare are highly multiplexed, patient-like standards that enable clinical research labs to properly develop, validate, monitor and standardise molecular next-generation sequencing (NGS) assays to support clinical evaluation and management of cancer and diseases. 

With targeted NGS panels increasingly being used to discover causative variants for inherited disease, the use of cell-line materials and remnant patient samples, which only cover a small subset of target variants, is no longer informative enough for the spectrum of mutations that need to be covered. These standards provide consistent positive and negative controls across broad variant types, and are formatted as purified DNA (gDNA), purified circulating tumor DNA (ctDNA) in synthetic plasma-like material, as well as formalin-fixed, paraffin-embedded (FFPE) material.

Benefits of using Seraseq NGS reference standards
• Highly multiplexed, patient-like standards
• Expert-designed constructs with clinical relevant variants
• Assess common, rare and technically challenging variants
• Coverage across SNVs, insertions and deletions
• Enables proper development, validation, monitoring and standardisation of NGS assays
• Available as gDNA, ctDNA, synthetic plasma-like material or FFPE material
• Full-process standards for end-to-end monitoring of NGS workflow
• Manufactured in cGMP-compliant and ISO 13485-certified facilities

Seraseq innovative design process

Design process

These clinically relevant reference materials cover the following functional areas:
• Solid tumor profiling
• Liquid biopsy
• Hematological malignancy
• Tumor mutational burden
• Inherited diseases

Material available for download
SeraCare clinical genomics flyer
SeraCare cancer solutions flyer
SeraCare inherited disease solutions flyer
SeraCare liquid Biopsy solutions flyer
Tech note: Assuring quality for somatic tumour mutation profiling with Seraseq Solid Tumor Mutations Mix-1 (AF20)
Tech note: Seraseq Circulating Tumor DNA-I Reference Materials for characterising, developing and validating plasma-based assays

Below is a small selection of reference standards available. Please use our search for the full list of reference standards available.

Seracare Reference Material, NGS Standards, SeraSeq


Note: product availability depends on country - see product detail page.

Details Cat number & supplier Size Price
Seraseq® FFPE WT (DNA/RNA) Reference Material 0710-0137 · LGC SeraCare
LGC SeraCare
1 FFPE curl (10 µm/tube) £400.00
1 FFPE curl (10 µm/tube)
Seraseq® Breast CNV Mix, +3 copies 0710-0411 · LGC SeraCare
LGC SeraCare
20 µl £813.00
20 µl
Seraseq® Lung & Brain CNV Mix, +3 copies 0710-0414 · LGC SeraCare
LGC SeraCare
20 µl £813.00
20 µl
Seraseq® FFPE Tumor Fusion RNA Reference Material v4 (replaces 0710-0129) 0710-0496 · LGC SeraCare
LGC SeraCare
1 FFPE curl/tube £546.00
1 FFPE curl/tube
Seraseq® FFPE NTRK Fusion RNA Reference Material 0710-1031 · LGC SeraCare
LGC SeraCare
1 FFPE curl/tube £664.00
1 FFPE curl/tube
Seraseq® ctDNA Mutation Mix v2 AF0.125% 0710-0143 · LGC SeraCare
LGC SeraCare
25 µl £1075.00
25 µl
Seraseq® FFPE Tumor Mutational Burden (TMB) Reference Material Score 26 0710-1307 · LGC SeraCare
LGC SeraCare
2 x 10 µm £1288.00
2 x 10 µm